Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00561483 · ClinicalTrials.gov registry record
Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 64
- Enrollment target
NCT00561483 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 64 participants.
The verdict
NCT00561483 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 64 participants
- Enrollment target
Study Summary
Renal Compromise after treatment of decompensated heart failure with diuretics is not uncommon. The purpose of our study is to investigate the relationship between cystatin C and worsening renal function in this setting. Cystatin C is a biomarker produced at a constant rate by all cells that is a sensitive biomarker of renal function.Cystatin C and Plasma amino terminal proB-type natriuretic peptide (NT-proBNP) levels will be obtained at baseline and daily. Our goal is to enroll 100 subjects with an estimated 5 samples per each subject. The time course of changes in cystatin C in relation to serum creatinine levels over time will be plotted. Our hypothesis is that sequential changes in cystatin C levels following initial treatment with diuretic therapy in the setting of acute decompensated heart failure may provide early insight into cardio-renal compromise. Understanding the natural history and time course of the changes in sequential cystatin C levels may facilitate further studies to guide the judicious use of diuretic therapy in acute decompensated heart failure, and to predict the risk of subsequent development of worsening renal function. If serial testing of cystatin C can provide accurate assessment and prediction of worsening renal function, clinical applications of these observations can be evaluated in future prospective studies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2007-12-05 |
| Est. Completion | 2016-10-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00561483
The ClinicalTrials.gov registry entry for NCT00561483 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00561483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00561483 about?
NCT00561483 is a clinical study titled "Sequential Cystatin C Levels and Renal Impairment in Acute Heart Failure". Renal Compromise after treatment of decompensated heart failure with diuretics is not uncommon. The purpose of our study is to investigate the relationship between cystatin C and worsening renal function in this setting. Cystatin C is a biomarker produced at a constant rate by all cells that is a se...
What is the current status of trial NCT00561483?
This trial is currently completed. The enrollment target is 64 participants. The study started on 2007-12-05. Estimated completion is 2016-10-14.
Who is sponsoring clinical trial NCT00561483?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.